Novavax (NASDAQ:NVAX) Announces Earnings Results, Beats Expectations By $0.24 EPS

Novavax (NASDAQ:NVAX) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.24, RTT News reports. During the same quarter last year, the business posted ($1.44) EPS.

Novavax Trading Down 3.6 %

Shares of Novavax stock traded down $0.26 during mid-day trading on Thursday, reaching $7.06. 8,933,731 shares of the stock were exchanged, compared to its average volume of 4,528,903. The company has a market cap of $1.13 billion, a price-to-earnings ratio of -3.12, a price-to-earnings-growth ratio of 2.85 and a beta of 2.14. The firm has a 50-day simple moving average of $8.55 and a 200 day simple moving average of $10.02. Novavax has a fifty-two week low of $3.81 and a fifty-two week high of $23.86.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $19.00 target price on shares of Novavax in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Novavax presently has a consensus rating of “Hold” and a consensus target price of $17.83.

Insiders Place Their Bets

In other Novavax news, Director Rachel K. King sold 4,150 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $9.02, for a total transaction of $37,433.00. Following the sale, the director now directly owns 14,770 shares in the company, valued at approximately $133,225.40. This trade represents a 21.93 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director James F. Young sold 4,600 shares of the firm’s stock in a transaction that occurred on Tuesday, December 24th. The stock was sold at an average price of $8.48, for a total transaction of $39,008.00. Following the sale, the director now owns 57,160 shares in the company, valued at $484,716.80. This trade represents a 7.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 14,150 shares of company stock valued at $119,641 in the last 90 days. 1.00% of the stock is currently owned by insiders.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.